Neuroendokrine Spätfolgen nach Hirntumoren im Kindesalter

Schagerl, S.; Lackner, Herwig; Benesch, Martin; Kerbl, Reinhold; Schwinger, Wolfgang; Dornbusch, Hans Jürgen; Sovinz, Petra; Urban, Ch.

doi:10.1007/s001120070007

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To a certain degree, decreased mortality is associated with increased long-term morbidity 1 . 1,2003 Brought to you by | University of California -San Francisco Authenticated Download Date | 2/20/15 5:23 PM sidered in patients treated by irradiation for CP, for a period of at least 5 years observation and comprehensive hormonal investigation including neuropsychiatric testing 9 . The risk of a second and subsequent malignant neoplasm (SMN) after successful tumor treatment was studied over a 20-year period by Gutjahr et al 5 and by Neglia et al 1 who reviewed a large cohort of more than 13,000 5-year survivors of childhood cancer.…”

Section: Discussionmentioning

confidence: 99%

Malignant Astrocytoma Arising 10 Years After Combined Treatment of Craniopharyngioma

Rittinger

Kranzinger²,

Jones³

et al. 2003

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Craniopharyngioma is the third most common intracranial tumor in childhood. Following surgery, virtually all patients present with hypopituitarism and are at considerable risk of tumor recurrence. Secondary tumors, however, are rare, occurring usually 10 years after diagnosis and associated with poor prognosis. We report on a 5 year-old boy in whom craniopharyngioma was diagnosed due to unilateral visual loss. After surgery he underwent conventional radiation therapy with a total tumor dose of 55 Gy, and had hormonal support with DDAVP, thyroxine, and a variable dose of hydrocortisone. Growth velocity declined slowly in the first 4 years, but improved later on again without GH therapy despite abnormal provocative tests. At the age of 15 years he developed peripheral facial nerve palsy due to a malignant astrocytoma (WHO grade III/IV). Repeated conventional radiation therapy with an additional stereotactic boost and chemotherapy could not prevent the fatal outcome. This observation may temper the use of radiosurgery in benign intracranial tumors.

show abstract

Section: Discussionmentioning

confidence: 99%